89BIO (ETNB) Stock Price, News & Analysis

Company Overview

89bio, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for metabolic and endocrine disorders. The company’s lead investigational asset, BIO89-100 (pegozafermin), is a long-acting analog of fibroblast growth factor 21 (FGF21) designed to address underlying drivers of nonalcoholic steatohepatitis (NASH), severe hypertriglyceridemia and related metabolic diseases. By leveraging protein engineering and proprietary delivery technologies, 89bio aims to improve metabolic health through targeted modulation of lipid and glucose pathways.

In addition to its NASH program, 89bio is exploring indications that include glycogen storage disease and other rare metabolic conditions with high unmet medical need. The company has advanced BIO89-100 into multiple clinical trials across North America and Europe, generating safety and efficacy data to support potential regulatory filings. Its research and development efforts are complemented by collaborations with academic centers and contract research organizations to accelerate patient enrollment and expand the understanding of FGF21 biology.

Headquartered in Redwood City, California, 89bio was founded in 2018 and completed its initial public offering on the NASDAQ under the ticker ETNB in 2022. Under the leadership of Chief Executive Officer Arndt Zhang, the company is building a pipeline of endocrine therapies aimed at transforming the treatment landscape for patients with chronic metabolic diseases.

Key Stats

• Today's Range: $14.84 to $14.91
• 50-Day Range: $7.97 to $14.96
• 52-Week Range: $4.16 to $15.06
• Volume: 4.35 million shs
• Average Volume: 2.61 million shs
• Market Capitalization: $2.20 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.81
• Consensus Rating: Moderate Buy

89BIO Stock Analysis - MarketRank™

89BIO scored higher than 50% of companies evaluated by MarketBeat, and ranked 549th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

89BIO has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 3 buy ratings, 5 hold ratings, and no sell ratings.

Upside Potential

89BIO has a consensus price target of $25.81, representing about 73.3% upside from its current price of $14.90.

Amount of Analyst Coverage

89BIO has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for 89BIO are expected to grow in the coming year, from ($3.19) to ($2.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of 89BIO is -4.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of 89BIO is -4.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

89BIO has a P/B Ratio of 4.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.34% of the float of 89BIO has been sold short.

Short Interest Ratio / Days to Cover

89BIO has a short interest ratio ("days to cover") of 9.8.

Change versus previous month

Short interest in 89BIO has recently increased by 4.93%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

89BIO does not currently pay a dividend.

Dividend Growth

89BIO does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.34% of the float of 89BIO has been sold short.

Short Interest Ratio / Days to Cover

89BIO has a short interest ratio ("days to cover") of 9.8.

Change versus previous month

Short interest in 89BIO has recently increased by 4.93%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.34

News Sentiment

89BIO has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 32 news articles for 89BIO this week, compared to 6 articles on an average week.

Search Interest

4 people have searched for ETNB on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

4 people have added 89BIO to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, 89BIO insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $115,280.00 in company stock.

Percentage Held by Insiders

Only 2.60% of the stock of 89BIO is held by insiders.

ETNB Stock Analysis - Frequently Asked Questions

How have ETNB shares performed this year?

89BIO's stock was trading at $7.82 on January 1st, 2025. Since then, ETNB shares have increased by 90.5% and is now trading at $14.8950.

How were 89BIO's earnings last quarter?

89BIO (NASDAQ:ETNB) announced its earnings results on Thursday, August, 7th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.22.

When did 89BIO IPO?

89BIO (ETNB) raised $70 million in an IPO on the week of November 11th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.

Who are 89BIO's major shareholders?

Top institutional investors of 89BIO include Westfield Capital Management Co. LP (2.31%), Geode Capital Management LLC (2.13%), Holocene Advisors LP (2.07%) and Assenagon Asset Management S.A. (1.49%). Insiders that own company stock include Ra Capital Management, LP, Rohan Palekar, Quoc Le-Nguyen, Michael R Hayden, Ryan Martins, Charles Mcwherter, Kathleen Laporte and Edward Morrow Atkinson III.
View institutional ownership trends.

How do I buy shares of 89BIO?

Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of 89BIO own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 89BIO investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walmart (WMT).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/22/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ETNB
• CIK: 1785173
• Web: www.89bio.com
• Phone: 415-432-9270
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for 89BIO: $25.81
• High Price Target: $49.00
• Low Price Target: $11.00
• Potential Upside/Downside: +73.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$367.08 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -94.48%
• Return on Assets: -80.92%

Debt

• Debt-to-Equity Ratio: 0.07
• Current Ratio: 15.19
• Quick Ratio: 15.19

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.34 per share
• Price / Book: 4.45

Miscellaneous

• Outstanding Shares: 148,308,000
• Free Float: 144,155,000
• Market Cap: $2.21 billion
• Optionable: Optionable
• Beta: 1.27